In contrast to entrectinib, a pan-TRK also inhibiting ROS1 and ALK and able to bypass the blood-brain barrier [132,133], larotrectinib acts as a selective inhibitor of all three NTRK proteins and was more extensively evaluated in patients with cancer [134]. Here, NTRK1 is linked to cancer.